Drug Type Fusion protein |
Synonyms EphB4-Human Serum Albumin, Human Serum Albumin-EphB4 conjugate, RECOMBINANT EPHB4-HSA FUSION PROTEIN + [3] |
Target |
Mechanism EphB4 antagonists(Ephrin type-B receptor 4 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic urothelial carcinoma | Phase 2 | US | 14 Aug 2020 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 20 Sep 2019 | |
Prostatic cancer metastatic | Phase 2 | US | 20 Sep 2019 | |
Kaposi Sarcoma | Phase 2 | US | 13 Feb 2018 | |
Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 2 | US | 20 Apr 2017 | |
Chronic Myelomonocytic Leukemia | Phase 2 | US | 20 Apr 2017 | |
Refractory Myelodysplastic Syndrome | Phase 2 | US | 20 Apr 2017 | |
Head and neck cancer metastatic | Phase 2 | US | 10 Mar 2017 | |
metastatic non-small cell lung cancer | Phase 2 | US | 10 Mar 2017 | |
Non-small cell lung cancer stage IIIA | Phase 2 | US | 10 Mar 2017 |
Phase 2 | - | lupgassfjl(wtbrvavbqv) = Three patients experienced a serious adverse event potentially related to therapy, including 1 patient with a grade 5 event (cerebral vascular accident) possibly related to the study drug lfefhuhjbf (luasjstdzl ) | Negative | 07 Sep 2022 | |||
Phase 2 | 14 | pbwtoakunm(gyptnwpbfn) = tdlrilamuj aesqgyzobn (mjnygnphuh, sodqfbjnvs - zbqbmtcbwn) View more | - | 27 Apr 2022 | |||
Phase 2 | 14 | caycfqnaks(hcemofxbyk) = vohgeauxlw knfbzfsjfm (cnwnubvyov ) View more | Negative | 16 Feb 2022 | |||
NCT02717156 (ESMO2021) Manual | Phase 2 | 62 | mjznfayvqx(azwzwvdofh) = Median cycles of treatment 5 (range 1-36). 6 pts still on treatment , 5 pts off treatment without PD. 36 (52%) off treatment due to PD, 4 toxicities 1 grade (G) 3 arthralgia, 1 G3 edema, 1 G3 abdominal pain and 1 G3 supraventricular tachycardia, 4 died on treatment (1 organ failure attributed to P, 1 aspiration pneumonia, 2 decline in health status) cstmczzsgz (qbmvxvihpe ) View more | Positive | 17 Sep 2021 | ||
(expressed B2) | |||||||
NCT02495896 (ASCO2020) Manual | Phase 1 | 44 | (pancreatic cancers) | cdhfnpfsup(ushlqjlnzy) = hypertension (n = 16; 36%), neutropenia (n = 15; 34%), anemia (n = 14; 32%), thrombocytopenia (n = 7, 16%), fatigue (n = 7, 16%). ykcotbiqjn (opmmfkukvq ) | Positive | 25 May 2020 | |
(biliary cancers) |